Background: Since human colon cancers often contain significant quantities of progastrin-processing intermediates, we sought to explore the possibility that the biosynthetic precursor of fully processed amidated gastrin, glycine-extended gastrin, may exert trophic effects on human colonic cancer cells. Materials and Methods: Binding of radiolabeled glycine-extended and amidated gastrins was assessed on five human cancer cell lines: LoVo, HT 29, HCT 116, Colo 320DM, and T 84. Trophic actions of the peptides were
Introduction
In addition to its role in the regulation of gastric acid secretion, gastrin is also a potent stimulant of gastrointestinal cell proliferation and differen-tiation (1) . However, the role of gastrin in the development of colorectal cancer has been controversial for many years (2) . Several studies demonstrated a growth-stimulatory effect of gastrin or pentagastrin on colon cancers in vivo and in vitro (3) (4) (5) whereas others have failed to confirm this effect (6, 7) . Other Fig. 1 . Gastrin post-translational processing.
Gastrin is synthesized on the endoplasmic reticulum and then transported to the Golgi. In well-differentiated neuroendocrine cells, progastrin is sorted in the trans-Golgi network to the regulated pathway of secretion and into secretory granules that contain the enzymes necessary to complete progastrin processing. In these granules, the amino-and carboxy-terminal flanking regions are cleaved by a prohormone convertase at dibasic arginine residues (ArgArg) and the carboxy-terminal arginines removed by carboxypeptidase H revealing G34-Gly. G34-Gly can then be amidated by the peptidyl-glycine alpha-amidating monooxygenase (PAM) to form G34-NH2 or cleaved at internal lysine/lysine (LysLys) residues resulting in the production of G17-Gly. Biosynthetic studies (64) suggest that although G34-NH2 can be cleaved at the LysLys site by a prohormone convertase to yield G17-NH2, G17-Gly is not amidated by PAM. Thus, G17-Gly may be a distinct end-product of progastrin processing in antral G-cells.
development of some human colonic and gastric tumors (8, 9) . Adding to the controversy is the fact that some investigators have found substantial quantities of gastrin within some human colon cancers whereas others have found little, if any, gastrin (2) . Recent studies have begun to resolve some of these conflicting data. Although gastrin gene expression can be found in normal human colonic tissues and many colon cancers, the 101 amino acid primary gastrin mRNA translation product, progastrin, requires extensive post-translational processing before it assumes its biologically relevant structure (10) . However, most "gastrin" antisera recognize only the fully mature 17 amino acid carboxyl-terminally amidated form of gastrin (G-NH2, Fig. 1 ). Since progastrin is often poorly processed in nonendocrine cells, such as those found in the colon, it explains why these "gastrin" antisera fail to detect significant quantities of peptide. Consistent with this notion is investigators' recent finding that colon cancers contain large amounts of progastrin and other progastrin-processing intermediates such as glycine-extended gastrin (G-Gly) but little fully processed G-NH2 (11) (12) (13) (14) .
To explore the possibility that progastrinprocessing intermediates play a role in gastrointestinal cell growth, we noted that G17-Gly stimulates the growth of an exocrine pancreatic cell line, AR4-2J, via receptors distinct from gastrin/ cholecystokinin-B (gastrin/CCKB) receptors (15) . We (11) and others (12) have detected progastrin-processing intermediates such as GGly in concentrations similar to that of G-NH2 in some colon cancers. Also, when the human gastrin gene is heterologously expressed in the liver of transgenic mice, there is an overproduction of unprocessed, but not processed, gastrin gene products (16) . This progastrin overproduction is associated with an increase in colonic mucosal proliferation, suggesting that progastrins play a role in colonic cell growth. Thus, in the present studies we sought to determine if human colon cancer cell lines express receptors for G-Gly that mediate its trophic effects. We also examined the proliferative effects of G-NH2 and G-Gly in combination on cells that express both receptors.
Materials and Methods

Cell Culture
The human colon cancer cell lines LoVo, HT 29 , HCT 116, Colo 320DM, and T 84 and the rat pancreatic tumor cell line AR4-2J were purchased from the American Type Culture Collection and grown in monolayer cultures in their appropriate growth media in an atmosphere of 95% air and 5% CO2 at 37°C. Cultures were passaged at 4-to 6-day intervals to maintain the cells at subconfluent densities.
Binding Studies
Human Leu'5-G17-NH2 (Research Plus, Bayonne, NJ) and Leu'5-G(2 17)-Gly (University of Michigan, protein core facility; peptide purity >95%, by HPLC and mass spectometry) were '251-labeled on Tyr'2 with an adaptation of the chloramine T method and purified by high-pressure liquid chromatography (HPLC) as described previously (15, 17) . The specific activities of the labels were 1.5 ,uCi/pmol. Binding assays were done on isolated cells that were detached in phosphate-buffered saline (PBS) containing 0.02% EDTA. Cells (2 X 106) were incubated with '25I-labeled Leu'5-G17-NH2 or Leu15-G(2 17)-Gly with or without 1 ,uM of unlabeled G17-NH2 or Leu'5-G(2 17)-Gly in a Krebs-N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer supplemented with 0.5% bovine serum albumin (BSA), 0.03% soybean trypsin inhibitor, and 0.05% bacitracin in a total volume of 1 ml at 37°C until equilibrium. Specific binding was calculated as the difference between the total amount of label bound and the amount of label remaining bound in the presence of 1 (25 ,M) . At the end of the incubation period, cells were washed and lysed, and luciferase assays were performed as previously described (18) . Luciferase activity was expressed as RLU (relative light units) and normalized for ,B-galactosidase activity. ,B-galactosidase activity was measured by the luminescent light derived from 10 ,ul of each sample incubated in 100 ,ul of Lumi-Gal 530 (Lumigen, Southfield, MI) and used to correct the luciferase assay data for transfection efficiency.
JUN KINASE ASSAY. Immunoprecipitations and the in-gel c-jun amino-terminal kinase (JNK) assays were performed as described (19) . Briefly, after a 30-min incubation with G-Gly (10-8 M), cells were lysed in 500 ,ul of lysis buffer [10 mM KPO4 (pH 7.4), 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM ,B-glycerophosphate, 1 mM sodium orthovanadate (Na3VO4), 2 mM dithiothreitol, 40 ,ug/ml phenylmethylsulfonyl fluoride, 10 nM okadaic acid, 0.8 ,ug/ml leupeptin, 10 mg/ml p-nitrophenylphosphate, and 10 jig/ml aprotinin], transferred into microfuge tubes, and spun at 16 ,000 x g for 10 min at 40C. Equal amounts of protein from each treatment group (1000 jug) were incubated with an anti-c-jun kinase 1-specific antibody (Santa Cruz Biotech-nology, Santa Cruz, CA) and mixed on a rotating platform for 15 hr at 4°C. Aliquots of protein A sepharose (Pharmacia, Piscataway, NJ) were then added and the solutions mixed for 1 additional hr. After centrifugation, pellets were washed two times with lysis buffer and resuspended in 20 ,A of electrophoresis buffer [for 10 ml: lml glycerol, 0.5 ml 2-mercaptoethanol, 3 ml 10% sodium dodecyl sulfate (SDS), 1.25 ml 1 M Tris buffer, 2 ml 0.1% bromophenol blue, 0.6 g urea], boiled for 5 min, and applied to a 10% SDS-polyacrylamide gel containing 0.5 mg/ml GST-c-Jun (Sigma) (20 (22) . One microgram of total RNA was reverse transcribed using a random primer p(dN)6. The PCR reaction was performed under the following conditions: 1 min at 94°C, 2 min at 550C, and 2 min at 720C for 40 cycles. As a control for contamination, the procedure was also performed using one tube without any input RNA. The amplified products were separated on a 1% agarose gel in 1 X TBE buffer, and then after denaturing (0.25 N HCI for 20 min, 0.5 M NaOH and 1.5 M NaCl for 30 min, and 1 M ammonium acetate and 0.1 M NaOH for 30 min), blotted to a nitrocellulose membrane and UV cross-linked. After a 2-hr prehybridization, the filter was hybridized with a 32P-labeled human gastrin cDNA probe in a 0.1 M HEPES (pH 7.5), 5X SSC, 5X Denhardt's solution with 100 ,ug/ml salmon sperm DNA for 3 hr at 600C. The membrane was washed two times in 2x SSC, 20 min each at 62°C, another 20 min in 1 X SSC at 620C, and finally for 10 min in I x SSC at 750C, and exposed to X-ray film at -80°C for 2 hr.
GASTRIN PEPTIDE ANALYSIS. For analysis of gastrin peptide expression, 2 X 106 cells (LoVo and HT 29) were plated in 6-cm dishes in their appropriate media and grown for 24 hr, then media were changed to serum-free media and after another 24 hr the serum-free media were collected. Media were centrifuged at 12,000 rpm for 5 min and stored at -20°C until assay. Media were analyzed by radioimmunoassay using antibody 5135, which is specific for amidated forms of gastrin and cross-reacts <1% with glycine-extended gastrins or progastrins extended beyond the carboxyl-terminal glycine residue (23) . GGly was quantified with antibody 8237, which cross-reacts <5% with amidated gastrins or progastrins extended beyond the carboxyl-terminal glycine residue (23 
Results
G-Gly and G-NH2 Receptor Binding
The presence of G-Gly-and G-NH2-selective binding sites on the different cell lines was investigated with '25I-labeled human Leu'5-G(2 17)-Gly and human Leu'5-G17-NH2 as described in Materials and Methods. AR4-2J cells were used as a positive control for both peptides in all experiments. None of the five different colon cancer cell lines showed significant specific binding sites for 1251-Leus5-G17-NH2 ( Fig. 2A) . 125i- (Fig. 3) . (Fig. 6 ). fection of the cells with a chimeric GAL4-Elk-1 expression vector and the 5Xgal-luciferase reporter plasmid. In this system GAL4-Elk-1 transactivates and stimulates luciferase activity only if the carboxyl terminus of Elk-I is phosphorylated by ERK2. We also wished to determine if G-Gly might also stimulate jun-kinase activity in these cells (19) . As shown in Figure 7 and HT 29, 1.1 ± 0.3). Next, we sought to determine if these effects on signal transduction were related to cell growth. As depicted in Figure 8 , the stimulatory effects of TPA (10 7 M) did stimulate jun-kinase activity in HT 29 and LoVo cells (Fig. 9) . We hypothesized that the enhancement of c-fos and c-jun expression by G17-NH2 and the G-Gly induced bioactivation of c-jun via junkinase were complementary in their biological actions. Thus, we incubated AR4-2J cells that express receptors for both G17-NH2 and G-Gly with these ligands. Both G17-NH2 (10-9 M, 145 ± 11%, n = 6) and Leu'5-G(2 17)-Gly M, 132 ± 8%, n = 6) stimulated increases in [3H]thymidine incorporation. However, both peptides together at 10-9 M significantly increased [3H]thymidine incorporation above the maximum level of either peptide alone (161 13%, n = 6) (Fig. 10) .
GASTRIN GENE EXPRESSION. We were not able to detect gastrin mRNA expression by northern blotting, but the expression of gastrin mRNA in LoVo and HT 29 cells could be determined by reverse transcribed (RT) PCR and Southern analysis. In both cell lines, amplification with primer 1 and primer 2 revealed a specific PCR product of 313 bp, with a much higher expression level in LoVo than in HT 29 cells (Fig. 11) . No PCR product was detected in the sample without any input RNA. G-NH2 and G-Gly were quantified by radioimmunoassay in serum-free LoVo and HT 29 media. Small amounts of G-NH2 were detected in media conditioned by both cell lines (LoVo, 5.6 ± 1.5 pmol/l; HT 29, 2.6 ± 0.6 pmol/l; mean ± SE), but G-Gly was detected in much higher concentrations (LoVo, 56 ± 18 pmol/l; HT 29, 79 ± 24 pmol/l; mean ± SE).
Discussion
The trophic effects of gastrin on gastrointestinal tissues have been known for quite some time -313 bp (1, 25) . However, the role of gastrin in the development of colorectal cancer has been controversial (3) (4) (5) (6) (7) 9, (26) (27) (28) (29) . One problem in many of these studies is that they generally examine the proliferative actions of the fully processed peptide amide. However, recent studies have noted that human colon cancers contain unprocessed gastrin precursors in amounts that exceed those of G-NH2 (11) (12) (13) (14) . Moreover, transgenic mice with elevated plasma levels of progastrin but not G-NH2 have an increased colonic proliferative index (16) .
Thus, we (30) and others (31) have sought to characterize the cellular and molecular mechanisms that may mediate the trophic effects of progastrin-processing intermediates on colonic mucosa. We have chosen to study extensively the physiologic effects of one gastrin-processing product, G-Gly. Interest in G-Gly has been fueled by the observations that G-Gly is stored in brain and gut tissues (32) (33) (34) and secreted with G-NH2 from antral G-cells into the circulation (35) , and achieves concentrations in plasma roughly equivalent to those of G-NH2 (36-38). Moreover, G-Gly is seen in greater concentrations than G-NH2 in some colon cancers (10) . Previously, we also identified G-Gly receptors, distinct from the gastrin/CCKB receptor that mediated the tropic effects of G-Gly on an exo-crine pancreatic cell line, AR4-2J ( 15) . Thus, we sought to determine if human colon cancers might produce G-Gly and express specific G-Gly receptors that mediate its trophic effects.
We noted a dose-dependent increase in [3H]thymidine incorporation in two (LoVo and HT 29) of the five human colonic cell lines with an EC50 of approximately 10 10 M (Fig. 5) . LoVo and HT 29 cells also demonstrated specific binding sites for 1251-Leu'5-G(2-17)-Gly (Figs. 2 and 4) .
Scatchard analysis revealed a Kd that was approximately 2 X 10-10 M for both cell lines, which is similar to the EC50 for growth (Fig. 3 ).
This suggests that these G-Gly binding sites mediate the proliferative effects of G-Gly. This notion is supported by the fact that G-Gly did not bind to or stimulate the growth of the three other tested cell lines. Additionally, the concentrations needed for cell growth are within the physiological range of G-Gly found in human plasma (39, 40) and similar to the Kd for rat pancreatic acinar cells, AR4-2J (15) . Finally, Koh et al. (41) have recently reported that G-Gly can act as a trophic agent in the mouse colon. In transgenic mice overexpressing G-Gly but not G-NH2 or progastrin they noted colonic cell hyperplasia.
To rule out the possibility that the G-Gly effects may be mediated by gastrin/CCKB receptors, we noted that '25I-Leu'5-G(2 17)-Gly binding could be displaced by neither G1 7-NH2 M) nor the gastrin/CCKB receptor antagonist PD-134308 (10-6 M) (Fig. 4) . Additionally, PD-134308 (10-6 M) did not inhibit the proliferative actions of G-Gly. Finally, G-NH2 did not bind to, nor stimulate the growth of, any of the five cell lines, suggesting that the actions of G-Gly are mediated by a receptor distinct from the gastrin/ CCKB receptor.
Identification of the contribution of gastrin to colon cancer cell growth has been difficult because a variety of gastrin receptors have been identified that appear to mediate gastrin's trophic effects (27, 31, 39, 40) . G-NH2 requires its carboxyl-terminal amide moiety for full biological activity mediated by gastrin/CCKB receptors. Indeed, removal of the carboxyl-terminal amide of G-NH2 completely abolishes its acid stimulatory effects mediated by standard gastrin/CCKB receptors and the immediate precursor of G-NH2, G-Gly, is at least four orders of magnitude less potent than G-NH2 in stimulating acid secretion from gastric parietal cells (42, 43) . However, gastrin/CCKB or CCKA receptor antagonists do not always inhibit the trophic actions of G-NH2, suggesting that these G-NH2 proliferative effects are mediated by non-A/non-B gastrin/CCK receptors (31, 39, 40) . The fact that we could not identify 125I-Leu'5-G17-NH2 binding sites (Fig. 2) or demonstrate an enhancement in [3H]thymidine incorporation with G17-NH2 on any of the five cell lines suggests that they do not express functional non-A/non-B CCK receptors. Moreover, it also suggests that the G-Gly receptor is distinct from previously described non-A/non-B gastrin/ CCK receptors (31, 39, 40) . It has also been demonstrated that antisense gastrin mRNA treatment of Colo 320 DM and HCT 116 cells results in an inhibition of cell proliferation (44) . Since we were unable to detect receptors for either amidated or glycine-extended gastrin on these cells, it is possible that receptors for progastrin peptides may be present on these cells. (Fig. 2) . As expected, we were also able to demonstrate the proliferative effects of G17-NH2 on the AR4-2J cells without being able to detect an enhancement in [3H]thymidine incorporation with G17-NH2 in any of the five cell lines. One possible explanation for the differences between the results of others and our findings is that we may be examining different subclones of LoVo and HT 29 cells.
In previous studies we had sought to examine the nuclear mechanisms that mediate the proliferative actions of G-NH2 and G-Gly (18, 24) . In AR4-2J cells, G-NH2, but not G-Gly, induces expression of the early response genes c-fos and c-jun (18) . c-fos activation is mediated via activation of MAP kinase and induction of SRE transcriptional activity via the MEK/MAP kinase pathway and the nuclear transcription factor Elk-1 (49-5 1) . To determine whether the G-Glyinduced proliferative effect in our cell lines depended on this pathway, we used the highly specific MEK inhibitor, PD 98509 (52 Since activation of JNK has been linked to Ras-dependent malignant transformation (54), we wished to determine if G-Gly might stimulate JNK activity, especially in view of the fact that G-Gly was not involved in MAP kinase pathway activation. As shown in Figure 9 , G-Gly markedly enhanced JNK activity in LoVo cells with a much smaller but nevertheless distinct effect in HT 29 cells. Although the level of JNK induction in HT 29 cells is less than that observed in LoVo cells, previous investigators have demonstrated different levels of JNK induction with the same ligand in different cell lines (55) . It is interesting to note that we did not observe Elk-I activation in these cells, even though JNK has been shown to activate Elk-I in some cells (56, 57) . In other cellular systems, however, JNK does not appear to activate Elk-i, as is the case in our human colon cancer cell lines (58, 59) . Finally, since others have noted induction of JNK activity during colonic tumorigenesis (60) , it is interesting to speculate on the role that G-Gly may play in this effect.
Although other mechanisms remain to be elucidated, our data suggest that G-NH2 and G-Gly stimulate growth via distinct yet complementary mechanisms. To determine if the events described above result in a complementary effect on growth, we incubated AR4-2J cells with G-NH2, G-Gly, and both peptides together. As previously reported (15), G-NH2 and G-Gly enhanced [3H]thymidine incorporation, but the use of the two peptides together at maximal doses resulted in a stimulation of [3H]thymidine incorporation significantly greater than the maximal effect of either peptide alone (Fig. 10 ). There are other data to support this notion that G-Gly works in a complementary fashion to enhance the biological activity of G-NH2 and other gastrointestinal peptides. Although acute administration of G-Gly has no effect on gastric acid secretion (42, 43) , chronic administration of G-Gly markedly enhances G-NH2-and histamine-stimulated acid secretion in vivo (61) and that from isolated parietal cells via an increase in the expression of the proton pump H+,K+-ATPase (62) .
It is interesting to speculate on the source of G-Gly responsible for cell growth in vivo. We noted that LoVo and HT 29 cells expressed the gastrin gene (Fig. 8) , as previously described by van Solinge et al. (14) . In contrast to these studies (14), we were able to detect small amounts of G-NH2 and G-Gly that were secreted from these cells. These findings suggest that human colon cancers produce gastrin-processing intermediates capable of stimulating their growth in an auto-crine fashion via cell surface receptors distinct from those that recognize G-NH2 (63) . This notion of an autocrine effect of gastrins on growth is supported by the observation that colonic cancer cell lines transfected with an antisense gastrin probe have reduced growth (44) . Conversely, it is also possible that growth could be stimulated by G-Gly secreted from other tissues since the Kd for G-Gly binding and the EC50 for its proliferative effects are well within the physiologic levels of G-Gly found in plasma (37, 38) .
